Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 5
Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
Published 16 August 2009 Volume 2009:5 Pages 661—669
DOI https://doi.org/10.2147/TCRM.S3427
Review by Single anonymous peer review
Peer reviewer comments 3
Sergio Carmona1, Osvaldo Bruera1,2
1Department of Neuro-otology and Pain and Headache, Instituto de Neurociencias de Buenos Aires INEBA, Buenos Aires, Argentina; 2Department of Pain and Headache, Fundación Favaloro, Buenos Aires, Argentina
Abstract: Migraine and migraine variants are common, chronic and incapacitating neurovascular disorders with a high impact on health resources. There is an extensive evidence base provided by double-blind, placebo-controlled trials showing that topiramate is a safe, effective and well tolerated drug in the management of migraine and its variants, being especially promising in the management of migraine-vertigo syndrome. Models both in the US and the UK have also shown that it offers a cost benefit when direct and indirect costs are evaluated, by reducing work loss, improving quality of life and reducing the use of increasingly scarce health resources.
Keywords: migraine, migraine prophylaxis, topiramate, quality of life, basilar migraine, cluster headache, vestibular migraine
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.